Date	Price Target	Rating	Analyst
8/4/2025		Underperform → Peer Perform	Wolfe Research
8/4/2025	$490.00	Perform → Outperform	Oppenheimer
7/30/2025	$370.00	Outperform	Raymond James
7/21/2025	$385.00	Buy	Truist
3/31/2025	$353.00	Buy	Redburn Atlantic
3/24/2025	$280.00 → $328.00	Neutral → Overweight	Analyst
11/12/2024		Peer Perform → Underperform	Wolfe Research
10/16/2024		Sector Outperform	Scotiabank

More analyst ratings

FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

6/14/22 9:45:06 AM ET

$ALNY

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALNY alert in real time by email

New Drug Application (NDA): 215515
Company: ALNYLAM PHARMS INC

Products on NDA 215515

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
AMVUTTRA	VUTRISIRAN	25MG	INJECTABLE;SUBCUTANEOUS	Prescription	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for NDA 215515

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
06/13/2022	ORIG-1	Approval	Type 1 - New Molecular Entity	PRIORITY		Label is not available on this site.

Get the next $ALNY alert in real time by email

Crush Q3 2025 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$ALNY

Date	Price Target	Rating	Analyst
8/4/2025		Underperform → Peer Perform	Wolfe Research
8/4/2025	$490.00	Perform → Outperform	Oppenheimer
7/30/2025	$370.00	Outperform	Raymond James
7/21/2025	$385.00	Buy	Truist
3/31/2025	$353.00	Buy	Redburn Atlantic
3/24/2025	$280.00 → $328.00	Neutral → Overweight	Analyst
11/12/2024		Peer Perform → Underperform	Wolfe Research
10/16/2024		Sector Outperform	Scotiabank

More analyst ratings

$ALNY
Press Releases

Fastest customizable press release news feed in the world

View All

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran's Differentiated Profile – − Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac Parameters – – In a Cohort of HELIOS-B Patients, CMR Imaging Showed Amyloid Regression in 22% of Vutrisiran Treated Patients with No Regression Found in Patients Who Received Placebo – – Treatment with Vutrisiran Preserved Kidney Function in HELIOS-B Patients, and Reduced Risk of Death and Cardiovascular Events in Patients with Advanced Chronic Kidney Disease – Alny

11/8/25 4:57:00 PM ET

$ALNY

Biotechnology: Pharmaceutical Preparations

Health Care

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: UBS Global Healthcare Conference on Monday, November 10, 2025, at 10:15 AM ET in Palm Beach Gardens, Florida Jefferies Global Healthcare Conference on Wednesday, November 19, 2025, at 11:30 AM GMT (6:30 AM ET) in London A live audio webcast of each presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. Replays will be available on the Alnylam website within 48 hours after each event. About Alnylam Pharmaceuticals Alnylam (NASDAQ:ALNY) has led

11/4/25 8:00:00 AM ET

$ALNY

Biotechnology: Pharmaceutical Preparations

Health Care

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

− Generated Q3 2025 Total Net Product Revenues of $851 Million (103% Growth Compared with Q3 2024), Driven Primarily by Total TTR Revenues of $724 Million (135% Growth Compared with Q3 2024) – − Continued Broad Access and Balanced Utilization of AMVUTTRA Across All ATTR-CM Patient Segments – − Presented New Data from the HELIOS-B Phase 3 Study at Major Congresses Demonstrating Vutrisiran's Long-Term Cardiovascular Benefit and Lower Rates of Gastrointestinal Events in ATTR-CM – − Advanced Multiple Pipeline Programs, Including Two New Phase 3 Trials, ZENITH for Zilebesiran in Hypertension, and TRITON-PN for Nucresiran in hATTR-PN – − Raises 2025 Guidance for TTR Franchise Net Revenues

10/30/25 8:00:00 AM ET

$ALNY

Biotechnology: Pharmaceutical Preparations

Health Care

$ALNY
Leadership Updates

Live Leadership Updates

View All

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

9/18/25 9:15:00 AM ET

$ALNY

$ILMN

Biotechnology: Pharmaceutical Preparations

Health Care

Medical Specialities

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has

3/5/25 7:00:00 AM ET

$ALNY

Biotechnology: Pharmaceutical Preparations

Health Care

ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th

3/5/24 9:06:00 AM ET

$ALNY

Biotechnology: Pharmaceutical Preparations

Health Care

$ALNY
Financials

Live finance-specific insights

View All

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

10/30/25 8:00:00 AM ET

$ALNY

Biotechnology: Pharmaceutical Preparations

Health Care

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday, October 30, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2025 results as well as expectations for the future via conference call on Thursday, October 30, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Ph

10/16/25 8:00:00 AM ET

$ALNY

Biotechnology: Pharmaceutical Preparations

Health Care

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

− Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – − Achieved Approximately 1,400 ATTR-CM Patients on AMVUTTRA® (vutrisiran) as of June 30, 2025 – − Obtained Approvals for AMVUTTRA for the Treatment of ATTR-CM in the European Union, Brazil, the United Kingdom and Japan – − Initiated TRITON-CM Phase 3 Trial of Nucresiran in Patients with Wild-Type or Hereditary ATTR-CM – − Raises 2025 Guidance for TTR Franchise Net Revenues to $2,175 Million to $2,275 Million; Total Net Product Revenues to $2,650 Million to $2,800 Million, Representing a $575 Mil

7/31/25 8:00:00 AM ET

$ALNY

Biotechnology: Pharmaceutical Preparations

Health Care

FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

Products on NDA 215515

Approval Date(s) and History, Letters, Labels, Reviews for NDA 215515

Original Approvals or Tentative Approvals

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $ALNY

FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

Products on NDA 215515

Approval Date(s) and History, Letters, Labels, Reviews for NDA 215515

Original Approvals or Tentative Approvals

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $ALNY

$ALNY SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Alnylam Pharmaceuticals Inc.

SEC Form 10-Q filed by Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ALNY Analyst Ratings

Alnylam Pharma upgraded by Wolfe Research

Alnylam Pharma upgraded by Oppenheimer with a new price target

Raymond James resumed coverage on Alnylam Pharma with a new price target

$ALNY FDA approvals

FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC